InvestorsHub Logo
Post# of 122024
Next 10
Followers 0
Posts 197
Boards Moderated 0
Alias Born 01/19/2005

Re: None

Tuesday, 05/24/2005 12:36:34 PM

Tuesday, May 24, 2005 12:36:34 PM

Post# of 122024
HEE Corporation Releases Preliminary Information on Pilot Study
Early Results Encouraging as Ten Patients Respond Positively to HPB-84 HUTCHINSON, Kan. - PRNewswire-FirstCall - May 24
HUTCHINSON, Kan., May 24 /PRNewswire-FirstCall/ -- HEE Corporation (OTC:HCCF) announces today that all nine of the original patients plus one additional patient will complete the 90-day pilot study on the effects of its Type II diabetes nutriceutical HPB-84 with positive improvements to their blood glucose levels.

According to HEE Corporation president Radley Brooks, "We are encouraged by both the efficacy and the patient tolerance of the subjects in our HPB-84 study. In essence, we're seeing marked improvement in the treatment of Type II diabetes with a regimen that includes HPB-84."

HEE Corporation has spent the past year testing and developing the promising nutriceutical for those who suffer from Type II diabetes. In April 2005, the company introduced a website that for the first time offered the product for sale to the general public. ( http://www.hpb84.net/ ). At the same time, a stringent testing program was underway with the goal of determining the overall effectiveness of HPB-84. Ten subjects were selected and on March 1, 2005 entered into a testing protocol designed to test the efficacy of HPB-84. At this point, half the subjects had completed the program, with several reducing the number of HPB-84 tablets taken daily as they reached their FBG (fasting blood glucose) levels earlier than expected. In addition, some of the patients were able to completely stop taking ancillary diabetic medications.

The test subjects will complete their testing regimen on May 27th, and HEE Corporation will release a final report on the effectiveness of its product on June 4. To this point, each subject has tolerated HPB-84 without adverse side effects, save for occasional low blood sugars which required patients to reduce diabetic medications and/or HPB-84. Laboratory safety data indicates no contraindication to continuing with HPB-84.

The http://www.hpb84.net/ website is a touchstone for those who may benefit from HPB-84. Customers have the opportunity to post their personal experiences with the product, and general information concerning testing, availability and corporate information will also be available.

About HEE
HEE's headquarters is based in Hutchinson, Kansas.